Published in
Elsevier, European Journal of Cancer, 12(51), p. 1511-1528, 2015
DOI: 10.1016/j.ejca.2015.04.026
Links
- ORCID
- Elsevier
- [hdl.handle.net]
- [hdl.handle.net]
- [eprints.whiterose.ac.uk] | PDF
- [eprints.whiterose.ac.uk] | PDF
- [www.researchgate.net] | PDF
Tools
Maintenance pazopanib versus placebo in non-small cell lung cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
Journal article published in 2015 by
Mary Er R. O'Brien,
Rabab Gaafar,
Baktiar Hasan,
Jessica Menis 
,
Tanja Cufer,
Sanjay Popat,
Penella J. Woll ,
Veerle Surmont,
Vassilis Georgoulias,
Ana Montes,
Fiona H. Blackhall,
Ivo Hennig,
Gerald Schmid-Bindert,
Paul Baas
,
Tanja Cufer,
Sanjay Popat,
Penella J. Woll ,
Veerle Surmont,
Vassilis Georgoulias,
Ana Montes,
Fiona H. Blackhall,
Ivo Hennig,
Gerald Schmid-Bindert,
Paul Baas
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Switch maintenance is an effective strategy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor (TKI). EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based chemotherapy in patients with advanced NSCLC.